Cargando…
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
SIMPLE SUMMARY: The PI3K/Akt/mTOR pathway plays a crucial role in cancer, including leukemia. Abnormalities in this pathway drive carcinogenesis by inducing uncontrolled growth, increased survival, and treatment resistance. The abovementioned pathway is also disrupted in various types of leukemia, w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648005/ https://www.ncbi.nlm.nih.gov/pubmed/37958470 http://dx.doi.org/10.3390/cancers15215297 |
_version_ | 1785135237855969280 |
---|---|
author | Wiese, Wojciech Barczuk, Julia Racinska, Olga Siwecka, Natalia Rozpedek-Kaminska, Wioletta Slupianek, Artur Sierpinski, Radoslaw Majsterek, Ireneusz |
author_facet | Wiese, Wojciech Barczuk, Julia Racinska, Olga Siwecka, Natalia Rozpedek-Kaminska, Wioletta Slupianek, Artur Sierpinski, Radoslaw Majsterek, Ireneusz |
author_sort | Wiese, Wojciech |
collection | PubMed |
description | SIMPLE SUMMARY: The PI3K/Akt/mTOR pathway plays a crucial role in cancer, including leukemia. Abnormalities in this pathway drive carcinogenesis by inducing uncontrolled growth, increased survival, and treatment resistance. The abovementioned pathway is also disrupted in various types of leukemia, which makes it a potential therapeutic target for this disease. Current treatment approaches for leukemia are limited and fraught with numerous side effects. This review article aims to summarize recent research data on inhibitors of the PI3K/Akt/mTOR pathway. Inhibition of this pathway may potentially provide improved treatment outcomes for leukemia. ABSTRACT: Blood malignancies remain a therapeutic challenge despite the development of numerous treatment strategies. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway plays a central role in regulating many cellular functions, including cell cycle, proliferation, quiescence, and longevity. Therefore, dysregulation of this pathway is a characteristic feature of carcinogenesis. Increased activation of PI3K/Akt/mTOR signaling enhances proliferation, growth, and resistance to chemo- and immunotherapy in cancer cells. Overactivation of the pathway has been found in various types of cancer, including acute and chronic leukemia. Inhibitors of the PI3K/Akt/mTOR pathway have been used in leukemia treatment since 2014, and some of them have improved treatment outcomes in clinical trials. Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies’ cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia. |
format | Online Article Text |
id | pubmed-10648005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106480052023-11-05 PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities Wiese, Wojciech Barczuk, Julia Racinska, Olga Siwecka, Natalia Rozpedek-Kaminska, Wioletta Slupianek, Artur Sierpinski, Radoslaw Majsterek, Ireneusz Cancers (Basel) Review SIMPLE SUMMARY: The PI3K/Akt/mTOR pathway plays a crucial role in cancer, including leukemia. Abnormalities in this pathway drive carcinogenesis by inducing uncontrolled growth, increased survival, and treatment resistance. The abovementioned pathway is also disrupted in various types of leukemia, which makes it a potential therapeutic target for this disease. Current treatment approaches for leukemia are limited and fraught with numerous side effects. This review article aims to summarize recent research data on inhibitors of the PI3K/Akt/mTOR pathway. Inhibition of this pathway may potentially provide improved treatment outcomes for leukemia. ABSTRACT: Blood malignancies remain a therapeutic challenge despite the development of numerous treatment strategies. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway plays a central role in regulating many cellular functions, including cell cycle, proliferation, quiescence, and longevity. Therefore, dysregulation of this pathway is a characteristic feature of carcinogenesis. Increased activation of PI3K/Akt/mTOR signaling enhances proliferation, growth, and resistance to chemo- and immunotherapy in cancer cells. Overactivation of the pathway has been found in various types of cancer, including acute and chronic leukemia. Inhibitors of the PI3K/Akt/mTOR pathway have been used in leukemia treatment since 2014, and some of them have improved treatment outcomes in clinical trials. Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies’ cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia. MDPI 2023-11-05 /pmc/articles/PMC10648005/ /pubmed/37958470 http://dx.doi.org/10.3390/cancers15215297 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wiese, Wojciech Barczuk, Julia Racinska, Olga Siwecka, Natalia Rozpedek-Kaminska, Wioletta Slupianek, Artur Sierpinski, Radoslaw Majsterek, Ireneusz PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title | PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title_full | PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title_fullStr | PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title_full_unstemmed | PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title_short | PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities |
title_sort | pi3k/akt/mtor signaling pathway in blood malignancies—new therapeutic possibilities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648005/ https://www.ncbi.nlm.nih.gov/pubmed/37958470 http://dx.doi.org/10.3390/cancers15215297 |
work_keys_str_mv | AT wiesewojciech pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT barczukjulia pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT racinskaolga pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT siweckanatalia pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT rozpedekkaminskawioletta pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT slupianekartur pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT sierpinskiradoslaw pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities AT majsterekireneusz pi3kaktmtorsignalingpathwayinbloodmalignanciesnewtherapeuticpossibilities |